Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2, Multicenter, Open-Label Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors Nivolumab or Pembrolizumab in Adult Patients With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1b/2, Multicenter, Open-Label Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors Nivolumab or Pembrolizumab in Adult Patients With Advanced Solid Tumors

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 23 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adegramotide/nelatimotide (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Cervical cancer; Colorectal cancer; Fallopian tube cancer; Gastric cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Urogenital cancer; Wilms' tumour
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms WIZARD101CI
  • Sponsors Boston Biomedical; Sumitomo Pharma America; Sumitomo Pharma Oncology

Most Recent Events

  • 25 Mar 2024 Status changed to discontinued, according to ClinicalTrials.gov record
  • 18 Nov 2022 Planned End Date changed from 1 Feb 2024 to 19 Nov 2022.
  • 13 Apr 2022 Results (at data cut-off: 30 March 2021; n=13) presented at the 113th Annual Meeting of the American Association for Cancer Research.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top